安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- IQIRVO® (elafibranor) | Official Patient Site
What is IQIRVO ® used for? IQIRVO is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA
- Elafibranor: Uses, Dosage, Side Effects, Warnings - Drugs. com
Elafibranor (Iqirvo) treats primary biliary cholangitis (PBC) with UDCA or alone FDA-approved PPAR agonist shown to reduce ALP levels in 51% of patients Learn about dosing, side effects, and cost assistance
- Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Elafibranor is an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist that decreases the toxic effects of bile acid and inflammation through downstream modulation of the
- Elafibranor - Wikipedia
Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis [4][8]
- Elafibranor (oral route) - Side effects dosage - Mayo Clinic
Elafibranor is used in combination with ursodeoxycholic acid (UDCA) to treat primary biliary cholangitis (PBC) in patients who have received UDCA but did not work well or used alone in patients who are unable to tolerate UDCA
- Iqirvo (elafibranor): Uses, Side Effects, Interactions . . . - WebMD
Iqirvo (elafibranor) is commonly used to treat primary biliary cholangitis (PBC) PBC is a rare liver disease that occurs when your body’s immune system incorrectly attacks your bile ducts
- label - Food and Drug Administration
IQIRVO (elafibranor) tablets are supplied as 80 mg film-coated tablets for oral administration Each tablet contains 80 mg elafibranor and the following inactive ingredients: colloidal silica
- Iqirvo | European Medicines Agency (EMA)
The active substance in Iqirvo, elafibranor, works by attaching to and activating cell receptors (targets) called 'PPAR receptors', which are thought to be involved in controlling the levels of bile acid and in the process of liver inflammation and scarring
|
|
|